Data from Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

Abstract

<div>Abstract<p><b>Purpose:</b> Recent evidence indicates that small noncoding RNA molecules, known as microRNAs (miRNAs), are involved in cancer initiation and progression. We hypothesized that genetic variations in miRNAs and miRNA target sites could be associated with the efficacy of androgen-deprivation therapy (ADT) in men with prostate cancer.</p><p><b>Experimental Design:</b> We systematically evaluated 61 common single nucleotide polymorphisms (SNPs) inside miRNAs and miRNA target sites in a cohort of 601 men with advanced prostate cancer treated with ADT. The prognostic significance of these SNPs on disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT were assessed by Kaplan–Meier analysis and Cox regression model.</p><p><b>Results:</b> Four, seven, and four SNPs were significantly associated with disease progression, PCSM, and ACM, respectively, after ADT in univariate analysis. <i>KIF3C</i> rs6728684, <i>CDON</i> rs3737336, and <i>IFI30</i> rs1045747 genotypes remained as significant predictors for disease progression; <i>KIF3C</i> rs6728684, <i>PALLD</i> rs1071738, <i>GABRA1</i> rs998754, and <i>SYT9</i> rs4351800 remained as significant predictors for PCSM; and <i>SYT9</i> rs4351800 remained as a significant predictor for ACM in multivariate models that included clinicopathologic predictors. Moreover, strong combined genotype effects on disease progression and PCSM were also observed. Patients with a greater number of unfavorable genotypes had a shorter time to progression and worse prostate cancer-specific survival during ADT (<i>P</i> for trend < 0.001).</p><p><b>Conclusion:</b> SNPs inside miRNAs and miRNA target sites have a potential value to improve outcome prediction in prostate cancer patients receiving ADT. <i>Clin Cancer Res; 17(4); 1–9. ©2010 AACR</i>.</p></div>